BioSpace News Archive

Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the first quarter ended March 31, 2020.

Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture, and sell patient-specific joint replacement implants designed to fit each patient’s unique anatomy, announced today financial results for the first quarter ended March 31, 2020.

Genocea Biosciences, Inc., a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host a KOL symposium with a live Q&A for analysts and investors to reflect on the progress of the T cell therapy landscape and provide an in-depth profile of GEN-011 – Genocea’s neoantigen cell therapy – on Tuesday, May 12th at 12:00 p.m. EDT.

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced it is reacquiring from Sandoz Inc. the rights to its SYMJEPI ® (epinephrine) Injection 0.3mg, SYMJEPI® (epinephrine) Injection 0.15mg products currently marketed and available in the United States.

Health Canada has contacted companies that may be importing or distributing certain respirators, including KN95 respirators, in Canada that may not meet safety and effectiveness standards to request that they immediately stop sale and relabel current stock as face masks (not respirators).

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the pricing of an underwritten public offering of 11,000,000 shares of common stock at a public offering price of $12.00 per share.

BioMarin Pharmaceutical Inc. announced the pricing of $550.0 million aggregate principal amount of 1.25% senior subordinated convertible notes due 2027 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, announced that researchers have developed a sensitive and specific serology test using the company’s ultra-sensitive Simoa platform for the detection and measurement of anti-SARS-CoV-2 IgG, IgM, and IgA antibodies against four immunogenic viral proteins.

As a result of the Global Pandemic of Covid-19, Obtain Medical (the sister company of the internationally respected Solve Distribution) has partnered with Olvad Holdings to respond and assist in giving their combined international support to this problem.

Exclusive Distribution agreement covers North America, Latin America, SE Asia, Europe · Validation of Gnomegen qPCR kits now complete at CLIA/CAP-certified lab partner · Focus now on commercialization of combination PCR/antibody testing paradigm REHOVOT, Israel, SINGAPORE and NEW YORK, NY, May 11, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB: TOMDF) , a commercial in vitro diagnostics company focused on the development of blood tests fo